By elucidating the mechanisms through which the c-Abl/RACK1/FAK pathway regulates the FMT process and ECM deposition, our study has provided further evidence that c-Abl is a potential therapeutic target for treating CDK and renal fibrosis, particularly in patients with c-Abl overexpression and/or activation. The gene discussed is ABL1; the disease is renal fibrosis.